Recent publications by Researchers affiliated with the Centre for Tropical Medicine and Global Health
Analytical Sensitivity Analysis and Clinical Impact Modeling of Rapigen Rapid Diagnostic Tests for Malaria.
Golden A. et al, (2024), The American journal of tropical medicine and hygiene, 111, 956 - 966
Evaluation of hydroxychloroquine or chloroquine for the prevention of COVID-19 (COPCOV): A double-blind, randomised, placebo-controlled trial.
Schilling WHK. et al, (2024), PLoS medicine, 21
Temporal changes in SARS-CoV-2 clearance kinetics and the optimal design of antiviral pharmacodynamic studies: an individual patient data meta-analysis of a randomised, controlled, adaptive platform study (PLATCOV)
Wongnak P. et al, (2024), The Lancet Infectious Diseases, 24, 953 - 963
Lineage-informative microhaplotypes for recurrence classification and spatio-temporal surveillance of Plasmodium vivax malaria parasites
Siegel SV. et al, (2024), Nature Communications, 15
Prevalence and genetic diversity of simian malaria in wild macaque populations across Thailand: Implications for human health.
Karnchaisri K. et al, (2024), Acta tropica, 254
Author Correction: Trio fluorophore-based phenotypic assay for the detection of artemisinin-induced growth-arrested Plasmodium falciparum in human erythrocytes.
Kobpornchai P. et al, (2024), Scientific reports, 14
Molecular markers of artemisinin resistance during falciparum malaria elimination in Eastern Myanmar.
Thu AM. et al, (2024), Malaria journal, 23
Primaquine in glucose-6-phosphate dehydrogenase deficiency: an adaptive pharmacometric assessment of ascending dose regimens in healthy volunteers.
Pukrittayakamee S. et al, (2024), eLife, 12
Clinical antiviral efficacy of favipiravir in early COVID-19 (PLATCOV): an open-label, randomised, controlled, adaptive platform trial
Luvira V. et al, (2024), BMC Infectious Diseases, 24
Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial
Schilling WHK. et al, (2024), The Lancet Infectious Diseases, 24, 36 - 45
Trio fluorophore-based phenotypic assay for the detection of artemisinin-induced growth-arrested Plasmodium falciparum in human erythrocytes.
Kobpornchai P. et al, (2024), Scientific reports, 14
A novel sensitive hexaplex high-resolution melt assay for identification of five human Plasmodium species plus internal control.
Srisutham S. et al, (2023), Acta tropica, 248
Clinical Antiviral Efficacy of Remdesivir in Coronavirus Disease 2019: An Open-Label, Randomized Controlled Adaptive Platform Trial (PLATCOV)
Jittamala P. et al, (2023), The Journal of Infectious Diseases, 228, 1318 - 1325
Pharmacokinetics of single low dose primaquine in Ugandan and Congolese children with falciparum malaria
Mukaka M. et al, (2023), eBioMedicine, 96, 104805 - 104805
Limited Polymorphism in the Dihydrofolate Reductase (dhfr) and dihydropteroate synthetase genes (dhps) of Plasmodium knowlesi isolate from Thailand.
Sangsri R. et al, (2023), Acta tropica
Evolution of genetic markers for drug resistance after the introduction of dihydroartemisinin-piperaquine as first-line anti-malarial treatment for uncomplicated falciparum malaria in Indonesia.
Rahmasari FV. et al, (2023), Malaria journal, 22
In vitro activity of rhinacanthin analogues against drug resistant Plasmodium falciparum isolates from Northeast Thailand.
Chaorattanakawee S. et al, (2023), Malar J, 22
Lineage-informative microhaplotypes for spatio-temporal surveillance of Plasmodium vivax malaria parasites.
Siegel SV. et al, (2023), medRxiv